Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Current Treatment Options in Oncology|June 18, 2016
Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential BiomarkersPanagiota Economopoulou, Ioannis Kotsantis, Amanda PsyrriCancers|November 18, 2020
Tumor Microenvironment and Immunotherapy Response in Head and Neck CancerPanagiota Economopoulou, Ioannis Kotsantis, Amanda PsyrriViruses|September 28, 2021
De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell CarcinomaPanagiota Economopoulou, Ioannis Kotsantis, Amanda PsyrriInternational Journal of Molecular Sciences|May 15, 2020
Special Issue about Head and Neck Cancers: HPV Positive CancersPanagiota Economopoulou, Ioannis Kotsantis, Amanda PsyrriExpert Opinion on Drug Safety|July 14, 2020
A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinomaPanagiota Economopoulou, Ioannis Kotsantis, Aristotelis BamiasESMO Open|August 30, 2017
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approachesPanagiota Economopoulou, Ioannis Kotsantis, Amanda PsyrriFrontiers in Oncology|September 27, 2019
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical SettingPanagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, et al.Oral Oncology|March 8, 2020
Nivolumab-related lichen planus of the lip in a patient with head and neck cancerPanagiota Economopoulou, Ourania Nicolatou-Galitis, Ioannis Kotsantis, et al.Oral Oncology|December 15, 2019
Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancerStergios Doumas, Periklis G Foukas, Panagiota Economopoulou, et al.Life (Basel, Switzerland)|June 27, 2024
Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical DataDimitra Smerdi, Myrto Moutafi, Ioannis Kotsantis, et al.Pageof 5